What is Artiva Biotherapeutics, Inc.'s AFS securities?

Artiva Biotherapeutics, Inc. (ARTV) reported AFS securities of $0 in Q1 2026.

What does AFS securities mean?

Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.

Artiva Biotherapeutics, Inc. ARTV AFS Securities

AFS Securities at other companies

Allogene TherapeuticsALLO

$0-100%

Nektar TherapeuticsNKTR

$162.99M+7,973%

Other financials

Income statement

See full

Revenue-—

Operating income-$24.4M-10.2%

Net income-$23.5M-15.8%

EPS (diluted)-$0.95-14.5%

Balance sheet

See full

Cash & equivalents$21.4M-30.6%

Total debt$10.3M-26.7%

Total equity$87.8M-48.0%

Total assets$106.0M-44.6%

Cash flow

See full

Operating cash flow-$21.0M-5.6%

CapEx$242.0K-52.6%

Free cash flow-$21.2M-4.1%

Valuation

See full

Market cap$429.03M+1,015%

Enterprise value$417.88M+1,832%

Profitability

See full

Operating margin-83.9%—

Net margin-79.3%—

Returns & leverage

See full

Return on equity-67.9%—

Debt / equity0.1×0.0×

Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s AFS securities?: Artiva Biotherapeutics, Inc. (ARTV) reported AFS securities of $0 in Q1 2026.
What does AFS securities mean?: Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.